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Abstract
Background: Type 2 diabetes (T2D) is a major cause of chronic kidney disease. Control of hypertension
and the use of angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II receptor blockers
especially in those with proteinuria have been shown to protect against chronic kidney disease and
delay its progression to kidney failure.
Methods: We reviewed the medical records of 169 patients at 12 months with a view of auditing the
screening for chronic kidney disease and the use of renoprotective measures.
Results: Urinalysis was done in 49.1% and serum creatinine in 50.3%. No patient had glomerular
filtration rate estimated. Seventy nine (67.6%) of the hypertensive patients were on anti-hypertensives.
ACEI was used in 49 (45.8%) of these patients BP control was optimal in 29.1%.
Conclusion: There is poor adherence to guidelines on chronic kidney disease screening and
renoprotection in T2D.
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Résumé
Fond: Le type 2 le diabète (T2D) est une cause importante de la maladie chronique de rein. La
commande de l'hypertension et l'utilisation des inhibiteurs d'enzyme convertissants d'angiotensine
(ACEI) et/ou des dresseurs de récepteur de l'angiotensine II particulièrement dans ceux avec le
proteinuria ont été montrées pour se protéger contre la maladie chronique de rein et pour retarder sa
progression à l'échec de rein.
Méthodes: Nous avons passé en revue les disques médicaux de 169 patients à 12 mois avec une vue
d'auditer le criblage pour la maladie chronique de rein et l'utilisation des mesures renoprotective.
Résultats: L'analyse d'urine a été faite en 49.1% et créatinine de sérum dans 50.3%. Aucun patient n'a
fait estimer le taux de filtrage glomérulaire. Soixante-dix-neuf (67.6%) des patients hypertendus étaient
sur des antihypertensifs. ACEI a été employé dans 49 (45.8%) de ces patients que la commande de BP
était optimale dans 29.1%.
Conclusion: Il y a d'adhérence pauvre aux directives sur le criblage et le renoprotection chroniques de
la maladie de rein dans T2D.
Mots-clés: La maladie chronique de rein, diabète, renoprotection
Chronic kidney disease (CKD) is of pandemic
proportion and a major cause of morbidity and
mortality worldwide. Current clinical practice
guidelines emphasize the need for prevention of end
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stage renal disease (ESRD) largely by the screening of
persons at increased risk of and early detection and
treatment of CKD.
1
Urine examination for markers of
kidney damage (like proteinuria and haematuria) and
an estimation of glomerular filtration rate (GFR) by
the Cock-Croft Gault (CG) formula
2
or the
Modification of Diet in Renal Disease (MDRD) study
derived equation
3
using serum creatinine form the
mainstay of this screening.
Type 2 Diabetes (T2D) is a major cause of CKD.
4, 5
Once overt nephropathy occurs there is a relentless
progression to ESRD. Control of hypertension and the
use of Angiotensin converting enzyme inhibitors
(ACEI) and/or Angiotensin II receptor blockers (ARB)
especially in those with proteinuria have been shown
to delay this progression.
6-8
This report describes
screening for CKD and renoprotection in T2D in a
teaching hospital in Nigeria. This audit would
contribute immensely to fighting the global scourge
of CKD.
Materials and Methods
We analyzed records of T2D patients being
followed up at the Diabetes Clinic of the Jos
University Teaching Hospital (JUTH) in a cross-
sectional study between June and September 2004.
Assessment of records was done at 12 months of
continued care at the clinic.
Clinical data analyzed included age, gender,
duration of diabetes, documentation of urinalysis and
estimation of GFR (eGFR) from serum creatinine
measurement. Other variables of interest were
treatment of hypertension and the use of ACEI/ARB.
Statistical analysis
Continuous variables were reported as
mean±standard deviation and categorical variables as
proportions. The Chi-Squared statistic was used to




Records of 169 consecutive type 2 diabetics (68
males and 101 females) were reviewed. One hundred
and seven (63.3%) patients were hypertensive and 62
(36.7%) non-hypertensive. The mean age of the
patients was 51±12 years. The duration of T2D
ranged from one (1) to 27 years with a median of
four (4) years.
Screening for CKD
Eighty three patients (49.1%) had urinalysis done.
Proteinuria was present 19.7% of those who had
urinalysis carried out. Serum creatinine was assayed
in 85 (50.3%) patients. None had eGFR documented.
Analysis of eGFR in those who had serum creatinine




Urinalysis was done in 47.7% of those with
hypertension and 52.3% of those without (OR 1.77,
95% CI 0.92- 3.40; p = .11). Similarly, serum creatinine
was done in 51.4% of those with hypertension and
48.6% of those without (OR 1.67, 95% CI 0.88- 3.16;
p = .11).
Renoprotection
Seventy nine (67.6%) of the hypertensive patients
were on treatment for hypertension and 28 (26.2%)
were not. ACEI was used in 49 (45.8%) of these
patients. BP control was satisfactory (<130/80 mm
Hg) only in 23 (29.1%) of the patients on treatment
for hypertension. Only two non-hypertensives were
on ACEI therapy. No patient (hypertensive or not)
was on ARB. The treatment of hypertension was ACEI
based in four (19.0%) of the patients with proteinuria
and four (16.7%) without (OR 1.17, 95% CI 0.25-
5.42).
Discussion
Main finding of the study
The main findings of our study were; 1) less than
half of the patients with T2D are screened for CKD; 2)
only two-thirds of T2D patients with hypertension are
on hypertensive medication. In addition, only a third
of those with hypertension had optimal BP control.
Screening for CKD
An earlier study in Nigeria showed that only




in a similar study of
Tunisian diabetics demonstrated that only 19.8% had
urinalysis done. The low screening rate for CKD is not
only limited to the “diabetic” population as a recent
survey revealed that only 26% of patients in primary
care had their GFR estimated.
11
The National Kidney
Foundation Kidney Disease Outcomes Quality
Initiative (KDOQI) clinical practice guidelines
recommend screening for CKD in at risk individuals
using proteinuria and the eGFR.
1
Renoprotection
As cardinal as BP control is to the prevention of
and slowing the progression of CKD, only a third of
our patients had optimal BP control. A similar figure
has been reported from Australia.
12
This corroborates
previous reports. The National Health and Nutrition
Examination Survey revealed that only 40% of US
hypertensive diabetics achieved blood pressure of
<130/80 mm Hg.
13
Lower figures (between 13% and
23%) have been reported in Europe.
14-16
Though ACEIs was used in nearly half of the
diabetics with hypertension in this study, the use of
ACEIs was scanty in those with proteinuria (19%).
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There was no patient on an ARB. Blockade of the
Renin-Angiotensin-Aldosterone system has been
shown to reduce proteinuria and retard the decline
of GFR in CKD. A recent survey in the UK showed that
32% of diabetics with proteinuria at CKD stage 3 were
on an ACEI and as much as 26% of diabetics with
hypertension were not on any BP lowering
medication regardless of the CKD stage.
17
In clinical
practice renoprotection is sub-optimal in T2D.
Adherence to international guidelines is no doubt
generally poor. The gap between guidelines and
clinical practice needs to be bridged. Regular audit,
continuing medical education, local adaptation of
international guidelines and action checklists have
been shown to improve the care of diabetics.
15, 18, 19
In conclusion, this study demonstrates a low
screening rate for CKD and an inadequate utilization
of renoprotection in T2D. The burden of CKD,
especially that due to T2D will remain unchecked
unless measures are instituted to improve adherence
to existing guidelines.
Acknowledgment
This data was presented at the 4th World Congress of
Nephrology organized by the International Society of Nephrology,
21-25 April, 2007, Rio de Janiero, Brazil.
References
1. National Kidney Foundation. K/DOQI Clinical Practice
Guidelines for Chronic Kidney Disease: Evaluation,
classification, and stratification. Am J Kidney Dis. 2002;
39:S1-S246.
2. Cockcroft DW, Gault MH. Prediction of creatinine
clearance from serum creatinine. Nephron. 1976;
16:31-41.
3. Levey AS, Bosch JP, Lewis JB, et al. A more accurate
method to estimate glomerular filtration rate from
serum creatinine: A new prediction equation.
Modification of Diet in Renal Disease Study Group.
Ann Intern Med. 1999; 130:461-470.
4. United States Renal Data System. USRDS. The United
States Renal Data System. Am J Kidney Dis. 2003; 42:1-
23.
5. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal
failure in type 2 diabetes: a medical catastrophe of
worldwide dimension. Am J Kidney Dis. 1999; 34:795-
808.
6. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of
antihypertensive therapy on the kidney in patients
with diabetes: A meta-regression analysis. Ann Intern
Med. 1993; 118:129-138.
7. Marre M, Chatellier G, Leblanc H, et al. Prevention of
diabetic nephropathy with enalapril in normotensive
diabetics with microalbuminuria. BMJ. 1988;
297:1092-1095.
8. Remuzzi G, Perico N, Macia M, et al. The role of renin–
angiotensin–aldosterone system in the progression of
chronic kidney disease. Kidney Int. 2005 ;( Suppl
99):S57-S65.
9. Okoro EO, Adejumo AO, Oyejola BA. Diabetic care in
Nigeria: report of a self-audit. J Diabetes
Complications. 2002; 16:159-164.
10. Harzallah F, Kanoun F, Elhouch F, et al. Quality of
ambulatory care of non-insulin dependent diabetic
patients. East Mediterr Health J. 2006; 12:98-104.
11. de Lusignan S. Chronic kidney disease. Br J Gen Pract.
2006; 56:885.
12. Bryant W, Greenfield JR, Chisholm DJ, et al. Diabetes
guidelines: easier to preach than to practice. Med J
Aust. 2006; 185:305-309.
13. Resnick HE, Foster GL, Bardsley J, et al. Achievement
of American Diabetes Association clinical practice
recommendations among U.S. adults with diabetes,
1999-2002: the National Health and Nutrition
Examination Survey. Diabetes Care. 2006; 29:531-537.
14. Eliasson B, Cederholm J, Nilsson P, et al. The gap
between guidelines and reality: Type diabetes in a
National Diabetes Register 1996-2003. Diabet Med.
2005; 22:1420-1426.
15. Madsbad S, Larsen ML, Adeler HF, et al.
Implementation of clinical guidelines in general
practice. The effect of journal audit and continuing
education for the treatment of cardiovascular risk
factors in patients with and without type 2 diabetes.
Ugeskr Laeger. 2006; 168:1640-1645.
16. Mallion JM, Kahn JC, Poncelet P, et al. Differences
between management guidelines and global health
strategies for arterial hypertension with metabolic
disorders in France in 1999. Ohara study. Arch Mal
Coeur Vaiss. 2001; 94:834-838.
17. New JP, Middleton RJ, Klebe B, et al. Assessing the
prevalence, monitoring and management of chronic
kidney disease in patients with diabetes compared
with those without diabetes in general practice.
Diabet Med. 2007; 24:364-369.
18. Kirkman MS, Williams SR, Caffrey HH, et al. Impact of a
program to improve adherence to diabetes guidelines
by primary care physicians. Diabetes Care. 2002;
25:1946-1951.
19. Schectman JM, Schorling JB, Nadkarni MM, et al. The
effect of physician feedback and an action checklist on
diabetes care measures. Am J Med Qual. 2004;
19:207-213.
